Cargando…
Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/ https://www.ncbi.nlm.nih.gov/pubmed/36307152 http://dx.doi.org/10.1136/jitc-2022-005257 |
_version_ | 1784821487039938560 |
---|---|
author | Park, Song Y Green, Austin R Hadi, Rouba Doolittle-Amieva, Coley Gardner, Jennifer Moshiri, Ata S |
author_facet | Park, Song Y Green, Austin R Hadi, Rouba Doolittle-Amieva, Coley Gardner, Jennifer Moshiri, Ata S |
author_sort | Park, Song Y |
collection | PubMed |
description | Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decrease of tumor size often occurs rapidly within the first 2–3 months, while improvement of the pigmentation takes several more months. Such clinical observation of lasting pigmentation could be explained by tumorous melanosis—a histopathological term referring to the presence of a melanophage-rich inflammatory infiltrate without remaining viable tumor cells. Herein, we report six patients with metastatic cutaneous melanoma who were treated with T-VEC. Biopsies were performed after observing clinical responses in the injected tumors. Pathological evaluation demonstrated non-viable or absent tumor tissue with tumorous melanosis in all cases. To accurately assess response to therapy and potentially decrease unnecessary additional T-VEC treatments, serial biopsy of ‘stable’ lesions should be considered to assess the presence or absence of viable tumor. |
format | Online Article Text |
id | pubmed-9621191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-96211912022-11-01 Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment Park, Song Y Green, Austin R Hadi, Rouba Doolittle-Amieva, Coley Gardner, Jennifer Moshiri, Ata S J Immunother Cancer Case Report Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decrease of tumor size often occurs rapidly within the first 2–3 months, while improvement of the pigmentation takes several more months. Such clinical observation of lasting pigmentation could be explained by tumorous melanosis—a histopathological term referring to the presence of a melanophage-rich inflammatory infiltrate without remaining viable tumor cells. Herein, we report six patients with metastatic cutaneous melanoma who were treated with T-VEC. Biopsies were performed after observing clinical responses in the injected tumors. Pathological evaluation demonstrated non-viable or absent tumor tissue with tumorous melanosis in all cases. To accurately assess response to therapy and potentially decrease unnecessary additional T-VEC treatments, serial biopsy of ‘stable’ lesions should be considered to assess the presence or absence of viable tumor. BMJ Publishing Group 2022-10-28 /pmc/articles/PMC9621191/ /pubmed/36307152 http://dx.doi.org/10.1136/jitc-2022-005257 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Park, Song Y Green, Austin R Hadi, Rouba Doolittle-Amieva, Coley Gardner, Jennifer Moshiri, Ata S Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
title | Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
title_full | Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
title_fullStr | Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
title_full_unstemmed | Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
title_short | Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
title_sort | tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/ https://www.ncbi.nlm.nih.gov/pubmed/36307152 http://dx.doi.org/10.1136/jitc-2022-005257 |
work_keys_str_mv | AT parksongy tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment AT greenaustinr tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment AT hadirouba tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment AT doolittleamievacoley tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment AT gardnerjennifer tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment AT moshiriatas tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment |